TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: initial reaction time in seconds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean reaction time in seconds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of recurrent AIS
Endpoint domain: Mortality/survival
Primary endpoint: Rate of ICH
Endpoint domain: Adverse events/effects
Primary endpoint: Area covered with biofilm on internal surfaces of complete dentures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight loss of ≥ 50% EWL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical activity of more than 30 min daily
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to recommended lifestyle changes
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: adiponectin receptor mRNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: peak flow readings increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: symptom scores decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical outcome after lumbar disc surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adherence to diet
Endpoint domain: Life impact
Endpoint subdomain: Dietary adherence
Primary endpoint: total adherence
Endpoint domain: Life impact
Endpoint subdomain: General adherence
Primary endpoint: Interindividual variability in CL/F
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary nitric oxide/creatinine (U NO/Cr) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of pollen-induced nasal eosinophilic inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mycological cure rate at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: delivered energy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: peak voltage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: pulse duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in surgical requirements for mastectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Degree of impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean number of microbial species
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Bloodstream Infection (BSI) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Hospital admissions for BSI
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Hospitalization days for BSI
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: incidence of bacteriuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Area under the concentration-time curve from time zero to 28 days (AUC(28))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed plasma concentration (C(max))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steady-state trough concentrations (C(trough))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intrasubject variation in fasting blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: tolerability of flupirtine
Endpoint domain: Adverse events/effects
Primary endpoint: effectiveness of flupirtine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in maximum interincisal opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mandibular function impairment score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reaction Time Standard Deviation (RTSD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Omission Errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Health Status/QoL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: spleen volume reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central corneal sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction of adverse symptoms after chromoendoscopy
Endpoint domain: Adverse events/effects
Primary endpoint: Perioperative respiratory adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Increased IMTG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postoperative surgical site infection rate
Endpoint domain: Adverse events/effects
Primary endpoint: mean reductions in intraocular pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: response-rate difference (RD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum CCL2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cytokine levels (ALP, IL-6, PGE-2, MMP-2, bFGF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete hematologic response (CHR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cytogenetic response (CCyR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 'don't know' response rates
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of women using effective contraception at follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peri-device flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of employees recruited
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of returning donors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of DGE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: delta E*
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subject preference for HW over OW
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mean number of days with headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of bone dust harvested
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time spent in bone dust collection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of bone dust infection
Endpoint domain: Adverse events/effects
Primary endpoint: Patent IRA (TIMI grade 2 or 3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: TIMI grade 3 patency rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total patency rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Role limitations due to physical functioning
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Therapy success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unified Parkinson's Disease Rating Scale (UPDRS) total
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Motor scale of UPDRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Activities of Daily Living scale of UPDRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: LOS basal pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amplitude of peristaltic waves
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: kilocalories burned
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total plasma lutein AUC(0‐72h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total plasma lutein AUC(0‐672h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C(max) for total lutein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasmic concentration of endothelin-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: thickness of the intima-media complex of the common carotid artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Proportion of women who delivered within 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Failure rate of abortion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: QOLRAD score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: 3% oxygen desaturation index (ODI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: IDL-C reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Neurological improvement measured by mRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in mean voids/24 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EPDS score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of women with EPDS >10
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in BMI z‐score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevalence of AUD/SUD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal change in serum creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: maximal change in blood urea nitrogen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: DFT voltage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: stored energy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Development of cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Recurrence of vaginal bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Death or severe disability at 90 days
Endpoint domain: Mortality/survival
Primary endpoint: End-stage renal disease (ESRD) progression
Endpoint domain: Mortality/survival
Primary endpoint: Liver stiffness score (LSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean reductions in pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of terminal hairs per cm2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of permanent atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Full return to work
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Productivity gains
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: postprandial metabolomic changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: urinary acylcarnitines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: fatty acid oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CPC 1/2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progressive disease at or before 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sensitivity for visualization of pulmonary arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diagnostic specificity for pulmonary arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Positive predictive value for pulmonary arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mucociliary clearance (AUC0‐6h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: incremental area under the curve for insulin (iAUCinsulin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: insulin sensitivity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: complication rate for end fractures
Endpoint domain: Adverse events/effects
Primary endpoint: exertional dyspnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Healthcare costs attributable to type 2 diabetes
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Hospital admissions due to complications
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Rate of severe general fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Mean ISQ value at 1-year follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Size of dentine tubules
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of occluded dentine tubules
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of defect height reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: horizontal bone gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine culture positivity rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Areas of hyperalgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Areas of allodynia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total IPSS improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-efficacy and control over memory management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: CD4(+)/CD8(+) T‐lymphocyte counts ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CD3 membrane expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Production of pro‐inflammatory prostaglandin‐E2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Neurologic adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Pain level measured by visual analogue scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for rescue analgesia (pentazocine)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Decrease in Hamilton Depression Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection error rate of automatic ECG-based measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Systolic blood pressure readings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Postnatal SUI improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean peak concentration of NO
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Scar elasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mean total MLSI change from baseline score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Class III malocclusion and negative overjet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anterior movement of the maxilla and surrounding soft tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retrusion of lower incisors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extent of corneal staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Violence at follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of asymptomatic ST depression episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cumulative duration of ST depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Accuracy in measuring blood glucose level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 10 mWT at self-selected speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 10 mWT at fast speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: M-MAS UAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: primary composite CV end point
Endpoint domain: Mortality/survival
Primary endpoint: number of interferon‐alpha doses tolerated
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: comfort with older people
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: understanding of physical decline in aging
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Confirmed cases of partner abuse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interventions offered
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: speed of cognitive processing
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Frequency of localization to the axilla
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first localization on preoperative lymphoscintigraphy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to harvest the first SLN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of treatment provided
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of wound healing at the stoma site
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement rates in the number of daily hot flushes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subjective evaluation of medical treatment outcome
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: shared decision making behaviour of physicians
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Frequency of severe CRBD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of paracetamol injections
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of pethidine injections
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Skeletal Muscle Mass (SMM) index loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean reduction in diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Knowledge, attitudes and beliefs scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Median duration of HSV‐1 shedding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Peak viral DNA load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Reduction in Y-MRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in vitamin and mineral serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in antioxidant defense
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV RNA suppression <50 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QT dispersion as a predictor of all-cause mortality risk
Endpoint domain: Mortality/survival
Primary endpoint: Temperature of lower extremity muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: telomere maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: drop in relative end‐tidal CO2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Primary composite endpoint of cardiovascular events
Endpoint domain: Mortality/survival
Primary endpoint: Time to administration of antibiotics after evidence of sepsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Readmission within 30 days of discharge
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Median rest verbal rating score for pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes